Leerink Partnrs Has Pessimistic Outlook of A Q1 Earnings

Agilent Technologies, Inc. (NYSE:A) – Equities research analysts at Leerink Partnrs dropped their Q1 2025 earnings per share estimates for Agilent Technologies in a research report issued on Tuesday, November 26th. Leerink Partnrs analyst P. Souda now anticipates that the medical research company will post earnings of $1.28 per share for the quarter, down from their prior forecast of $1.36. The consensus estimate for Agilent Technologies’ current full-year earnings is $5.72 per share. Leerink Partnrs also issued estimates for Agilent Technologies’ Q2 2025 earnings at $1.33 EPS, Q3 2025 earnings at $1.41 EPS, Q4 2025 earnings at $1.55 EPS, FY2025 earnings at $5.57 EPS and FY2026 earnings at $6.10 EPS.

A number of other equities analysts have also commented on A. Bank of America lifted their price objective on Agilent Technologies from $140.00 to $147.00 and gave the stock a “neutral” rating in a research note on Thursday, August 22nd. Barclays lowered their target price on Agilent Technologies from $145.00 to $135.00 and set an “underweight” rating for the company in a report on Wednesday. Evercore ISI lifted their target price on Agilent Technologies from $135.00 to $145.00 and gave the stock an “in-line” rating in a report on Tuesday, October 1st. Sanford C. Bernstein lowered their target price on Agilent Technologies from $140.00 to $135.00 and set a “market perform” rating for the company in a report on Tuesday. Finally, JPMorgan Chase & Co. lowered their target price on Agilent Technologies from $165.00 to $160.00 and set an “overweight” rating for the company in a report on Tuesday. One equities research analyst has rated the stock with a sell rating, seven have given a hold rating and eight have assigned a buy rating to the company’s stock. According to MarketBeat.com, the company currently has an average rating of “Hold” and an average target price of $143.40.

Agilent Technologies Price Performance

Agilent Technologies stock opened at $138.11 on Wednesday. The stock’s 50 day moving average is $137.72 and its 200 day moving average is $137.43. The company has a debt-to-equity ratio of 0.36, a current ratio of 1.78 and a quick ratio of 1.37. The firm has a market cap of $39.68 billion, a P/E ratio of 31.25, a P/E/G ratio of 5.91 and a beta of 1.07. Agilent Technologies has a one year low of $124.10 and a one year high of $155.35.

Institutional Investors Weigh In On Agilent Technologies

Several institutional investors have recently bought and sold shares of A. Menard Financial Group LLC boosted its position in Agilent Technologies by 1.6% in the second quarter. Menard Financial Group LLC now owns 4,845 shares of the medical research company’s stock worth $628,000 after purchasing an additional 77 shares during the last quarter. McAdam LLC boosted its position in Agilent Technologies by 3.1% in the third quarter. McAdam LLC now owns 2,531 shares of the medical research company’s stock worth $376,000 after purchasing an additional 77 shares during the last quarter. Brown Brothers Harriman & Co. boosted its position in Agilent Technologies by 13.5% in the third quarter. Brown Brothers Harriman & Co. now owns 646 shares of the medical research company’s stock worth $96,000 after purchasing an additional 77 shares during the last quarter. Global Retirement Partners LLC boosted its position in Agilent Technologies by 3.2% in the third quarter. Global Retirement Partners LLC now owns 2,570 shares of the medical research company’s stock worth $382,000 after purchasing an additional 79 shares during the last quarter. Finally, Rovin Capital UT ADV boosted its position in Agilent Technologies by 1.6% in the third quarter. Rovin Capital UT ADV now owns 5,049 shares of the medical research company’s stock worth $750,000 after purchasing an additional 81 shares during the last quarter.

Insider Buying and Selling

In related news, SVP Dominique Grau sold 9,990 shares of the company’s stock in a transaction on Thursday, September 26th. The stock was sold at an average price of $145.00, for a total transaction of $1,448,550.00. Following the completion of the sale, the senior vice president now owns 40,011 shares in the company, valued at approximately $5,801,595. This represents a 19.98 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this link.

Agilent Technologies Increases Dividend

The business also recently declared a quarterly dividend, which will be paid on Wednesday, January 22nd. Investors of record on Tuesday, December 31st will be issued a dividend of $0.248 per share. The ex-dividend date of this dividend is Tuesday, December 31st. This represents a $0.99 annualized dividend and a yield of 0.72%. This is an increase from Agilent Technologies’s previous quarterly dividend of $0.24. Agilent Technologies’s dividend payout ratio is 21.27%.

Agilent Technologies Company Profile

Agilent Technologies, Inc provides application focused solutions to the life sciences, diagnostics, and applied chemical markets worldwide. The company operates in three segments: Life Sciences and Applied Markets, Diagnostics and Genomics, and Agilent CrossLab. The Life Sciences and Applied Markets segment offers liquid chromatography systems and components; liquid chromatography mass spectrometry systems; gas chromatography systems and components; gas chromatography mass spectrometry systems; inductively coupled plasma mass spectrometry instruments; atomic absorption instruments; microwave plasma-atomic emission spectrometry instruments; inductively coupled plasma optical emission spectrometry instruments; raman spectroscopy; cell analysis plate based assays; flow cytometer; real-time cell analyzer; cell imaging systems; microplate reader; laboratory software; information management and analytics; laboratory automation and robotic systems; dissolution testing; and vacuum pumps, and measurement technologies.